Nico.lab has successfully won the bid for a tender issued by international pharmaceutical company Bayer. For the coming three years, Nico.lab will act as the core lab for the project and coordinate the collection of data from 15 sites in Germany, providing them with standard operating procedures and managing the transfer of imaging data. Nico.lab will then employ its own expertise and technology to process and analyse the data from over 600 patients. The trial, which is part of a larger project investigating a new treatment for aortic valve replacement, will assess which compounds are most effective in preventing cerebral infarction after valve replacement. Nico.lab's technology is a valuable tool in trials of this nature.